Facebook Instagram Twitter Linkedin Youtube Podcast
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne
June 7, 2023
Antisense Announces First Patient Dosed in ATL1102 Phase IIb Duchenne Trial
June 8, 2023

Sarepta Provides Update for SRP-9001-303: ENVISION study enrollment in U.S.

June 8, 2023

On June 8, 2023, Sarepta Therapeutics shared important enrollment updates about their ENVISION study (SRP-9001-303).

Please read their Community Letter by clicking here.

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2024 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*) 





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Register Now

    Experience the magic this summer!

    Apply Today

    How is the rare disease community accomplishing goals?

    Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

    Register Today

    Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

    Give Today

    Accessible Vehicle Fund Applications Open

    Apply Today